SCHEMBL27010664

SCHEMBL27010664

CC(C)N(C)C1CCCCC1NCc1cccnc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.54
ALDH1A1 P00352 2/20 0.54
PKM P14618 2/20 0.54
IKZF2 Q9UKS7 1/20 0.47
KDM1A O60341 2/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
HSD17B10 Q99714 2/20 0.43
GAA P10253 1/20 0.43
MGAM O43451 1/20 0.42
SI P14410 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
TACR1 P25103 1/20 0.41
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26620798 0.87 ALDH1A1 (0.59) KDM4EALDH1A1PKMIKZF2KDM1A
SCHEMBL27010660 0.85 HTT (0.42) KDM4EPKMKDM1AMAOAMAOB
SCHEMBL27010644 0.84 IKZF2 (0.43) IKZF2KDM1AMAOATACR1KMT2A
SCHEMBL27010662 0.81 ALDH1A1 (0.61) KDM4EALDH1A1PKMKDM1AMAOA
SCHEMBL27010700 0.79 KDM4E (0.52) KDM4EALDH1A1PKMLMNATSHR
SCHEMBL26620797 0.78 ALDH1A1 (0.64) KDM4EALDH1A1PKMKDM1AMAOA
SCHEMBL27010641 0.77 MAOA (0.47) ALDH1A1KDM1AMAOAMAOBSMN1; SMN2
SCHEMBL27010657 0.76 ALDH1A1 (0.36) KDM4EALDH1A1KDM1AMAOAMAOB
SCHEMBL24315799 0.74 ALDH1A1 (0.50) KDM4EALDH1A1PKMLMNATSHR
SCHEMBL8226104 0.72 ALDH1A1 (0.97) KDM4EALDH1A1PKMKDM1AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 KDM4E 791/4885ALDH1A1 2267/4885PKM 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.